Presentations

Presentations

Presentations

PRESENTATIONS

Date Title Documents

“First Results of a Head-to-Head Trial of Pegunigalsidase Alfa vs. Agalsidase Beta in Fabry Disease: 2-year Results of the Phase 3 Randomized, Double-blind, BALANCE Study,” Presentation By Eric L. Wallace, M.D., at the 19th Annual WorldSymposium 2023

“Long-term Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease: 2-year Interim Results from the Ongoing Phase 3 BRIGHT51 Open-label Extension Study”

“Long-term Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease: 2-year Interim Results from the Ongoing Phase 3 BRIGHT51 Open-label Extension Study,” Poster Presentation By John Bernat, M.D., Ph.D.

“First Results of a Head-to-Head Trial of Pegunigalsidase Alfa vs. Agalsidase Beta in Fabry Disease: 2-year Results of the Phase 3 Randomized, Double-blind, BALANCE Study,” Poster Presentation By Eric L. Wallace, M.D.

KOL Event Presentation – Myrl D. Holida, PA-C

PLX Corporate Presentation (December 2022)

Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease - Results from the Phase 3, Open-Label, BRIGHT Study; Poster from the 7th Update on Fabry Disease

Long-term Safety and Efficacy of Pegunigalsidase Alfa - A Multicenter Extension Study in Adult Patients with Fabry Disease; Abstract from the 7th Update on Fabry Disease

Safety and Efficacy of Pegunigalsidase Alfa vs Agalsidase Beta on Renal Function in Fabry Disease - 24-Month Results from the Phase III Randomized, Double-blind, BALANCE Study; Poster from the 7th Update on Fabry Disease

Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease - Results from the Phase 3, Open-label, BRIGHT Study; Abstract from the 7th Update on Fabry Disease

Tolerability and Infusion Duration of Pegunigalsidase Alfa in Patients With Fabry Disease - Data From 5 Completed Clinical Trials; Abstract from the 7th Update on Fabry Disease

Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease - 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-label Study; Abstract from the 7th Update on Fabry Disease

Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease - 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-Label Study; Poster from the 7th Update on Fabry Disease

Tolerability and Infusion Duration of Pegunigalsidase Alfa in Patients with Fabry Disease - Data from 5 Completed Clinical Trials; Poster from the 7th Update on Fabry Disease